Table 1 Recent clinical trials of CAR T-cell therapy in glioblastoma (in alphabetical order)
From: Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight
Target | Study title | Phase | Status | Institution and location |
|---|---|---|---|---|
CAR T-cell therapy | ||||
 B7-H3 | Pilot study of B7-H3 CAR-T in treating patients with recurrent and refractory glioblastoma. NCT04385173 | 1 | Recruiting | Second Affiliated Hospital, School of Medicine, Zhejiang University, China |
B7-H3 CAR-T for recurrent or refractory glioblastoma. NCT04077866 | 1/2 | Recruiting | Second Affiliated Hospital, School of Medicine, Zhejiang University, China | |
 Chlorotoxin | Chimeric antigen receptor (CAR) T cells with a cholrotoxin tumor-targeting domain for the treatment of MPP2+ recurrent or progressive glioblastoma. NCT04214392 | 1 | Recruiting | City of Hope Medical Center, CA, United States |
 EGFRvIII | CAR T cell receptor immunotherapy targeting EGFRvIII for patients with malignant gliomas expressing EGFRvIII. NCT01454596 | 1/2 | Completed | National Institutes of Health Clinical Center, United States |
Intracerebral EGFR-vIII CAR-T cells for recurrent GBM. NCT03283631 | 1 | Suspended | Duke University Medical Center, NC, United States | |
Pilot study of autologous anti-EGFRvIII CAR T cells in recurrent glioblastoma multiforme. NCT02844062 | 1 | Unknown status | Sanbo Brain Hospital Capital Medical University, Beijing, China | |
Memory-enriched T cells in treating patients with recurrent or refractory grade III–IV glioma. NCT03389230 | 1 | Recruiting | City of Hope Medical Center, CA, United States | |
 EphA2 | CAR-T cell immunotherapy for EphA2 positive malignant glioma patients. NCT02575261 | 1 / 2 | Withdrawn | Central Laboratory in Fuda Cancer Hospital, Guangdong, China |
 GD2 | C7R-GD2.CAR T cells for patients with GD2-expressing brain tumors (GAIL-B). NCT04099797 | 1 | Recruiting | Baylor College of Medicine, TX, United States |
Personalized chimeric antigen receptor T cell immunotherapy for patients with recurrent malignant gliomas. NCT03423992 | 1 | Recruiting | Xuanwu Hospital, Beijing, China | |
HER2 | Intracranial injection of NK-92/5.28.z cells in patients with recurrent HER2-positive glioblastoma. NCT03383978 | 1 | Recruiting | Senckenberg Institute of Neurooncology, Frankfurt, Germany |
CMV-specific cytotoxic T lymphocytes expressing CAR targeting HER2 in patients with GBM. NCT01109095 | 1 | Completed | Baylor College of Medicine, TX, United States | |
 IL13Ra2 | Genetically modified T cells in treating patients with recurrent or refractory malignant glioma. NCT02208362 | 1 | Recruiting | City of Hope Medical Center, CA, United States |
Phase I study of cellular immunotherapy for recurrent/refractory malignant glioma using intratumoral infusions of GRm13Z40-2, an allogeneic CD8+ cytolitic T-cell line genetically modified to express the IL 13-Zetakine and HyTK and to be resistant to glucocorticoids, in combination with interleukin-2. NCT01082926 | 1 | Completed | City of Hope Medical Center, , CA, United States | |
CAR T-cell therapy in combination with chemotherapy | ||||
 EGFRvIII | Immunogene-modified T (IgT) cells against glioblastoma multiforme. NCT03170141 | 1 | Enrolling by invitation | Shenzhen Geno-immune Medical Institute, Guangdong, China |
CAR T-cell therapy in combination with immune check point inhibitors | ||||
 EGFRvIII | CART-EGFRvIII + pembrolizumab in GBM. NCT03726515 | 1 | Active, not recruiting | Abramson Cancer Center of the University of Pennsylvania, PA, United States |
 IL13Ra2 | IL13Ralpha2-targeted chimeric antigen receptor (CAR) T cells with or without nivolumab and ipilimumab in treating patients with recurrent or refractory glioblastoma. NCT04003649 | 1 | Recruiting | City of Hope Medical Center, CA, United States |